Frovatriptan use in migraineurs with or at high risk of coronary artery disease

Headache

Volumn 44, Issue 5, 2004, Pages 403-410

  Elkind, Arthur H ^a   Satin, Lawrence Z ^b   Nila, Alice ^b   Keywood, Charlotte ^c  

^a Elkind Headache Center   (United States)

^b Central Cardiac Testing   (United States)

^c Minerva Pharmaceutical Consulting   (United Kingdom)

Author keywords

Coronary disease; Migraine; Triptans

Indexed keywords

FROVATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG USE; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART RATE; HIGH RISK POPULATION; HOLTER MONITORING; HUMAN; MIGRAINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ARRHYTHMIA; BLOOD PRESSURE; CARBAZOLES; CORONARY ARTERIOSCLEROSIS; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RISK FACTORS; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 2542474169     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2004.04071.x     Document Type: Article

References (14)

1. Goadsby PJ. A triptan too far? J Neurol Neurosurg Psychiatry. 1998;64:143-147.
2. Brown EG, Endersby CA, Smith RN, Talbot JC. The safety and tolerability of sumatriptan: an overview. Eur Neurol. 1991;31:339-344.
3. Willett F, Curzen N, Adams J, Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan [case report]. BMJ. 1992;304:1415.
4. Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. Headache. 1996;36:329-331.
5. Parsons AA, Parker SG, Raval P, et al. Comparison of the cardiovascular effects of the novel 5-HT(1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs. J Cardiovasc Pharmacol. 1997;30:136-141.
6. Parsons AA, Raval P, Smith S, et al. Effects of the novel high-affinity 5-HT(1B/1D) receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol. 1998;32:220-224.
7. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. 1st ed. Cephalalgia. 1991;11:1-112.
8. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-362.
9. 1B/1D agonist for the acute treatment of migraine on the cardiovascular system of healthy male volunteers. Presented at: the American Association for the Study of Headache; June 26-28, 1998; San Francisco, Calif.
10. Jhee SS, Salazar DE, Ford NF, Fulmor IE, Sramek JJ, Cutler NR. Monitoring of acute migraine attacks: placebo response and safety data. Headache. 1998;38:35-38.
11. Rautaharju PM, Manolio TA, Furberg CD, et al. Ischemic episodes in 24-h ambulatory electrocardiograms of elderly persons: the Cardiovascular Health Study. Int J Cardiol. 1995;51:165-175.
12. Asmar R, Benetos A, Pannier B, et al. Prevalence and circadian variations of ST-segment depression and its concomitant blood pressure changes in asymptomatic systemic hypertension. Am J Cardiol. 1996;77:384-390.
13. May O, Arildsen H, Damsgaard EM, Mickley H. Prevalence and prediction of silent ischaemia in diabetes mellitus: a population-based study. Cardiovasc Res. 1997;34:241-247.
14. Géraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache. 2002;42(suppl 2):S93-S99.